Memantine Hydrochloride Capsule, Extended Release
Product Images NDC 68382-547

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 68382-547). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine HCl Er Capsules (Ad59ebbd 2896 48a1 A53c 719c04593a9a 01)

Chemical structure of Memantine hydrochloride, showing the bicyclo[2.2.1]heptane framework with an amino group and methyl substituents, along with the hydrochloride (HCl) salt representation.*

FDA Label Image

Memantine HCl Er Capsules (Ad59ebbd 2896 48a1 A53c 719c04593a9a 02)

A line graph showing the mean change from baseline in SIB score over 24 weeks of treatment, comparing Memantine hydrochloride extended-release capsule 28 mg to placebo. The x-axis represents weeks of treatment, and the y-axis shows mean change in SIB score with clinical improvement above zero and clinical decline below. Memantine shows a sustained improvement in SIB score compared to placebo over the treatment period.*

FDA Label Image

Memantine HCl Er Capsules (Ad59ebbd 2896 48a1 A53c 719c04593a9a 03)

A cumulative percentage curve graph showing patients' SIB (Severe Impairment Battery) change from baseline. The X-axis represents SIB change from baseline, ranging from 40 to -50, and the Y-axis shows cumulative percentage of patients from 0 to 100%. Two data lines are compared: Memantine hydrochloride extended-release capsule 28 mg and Placebo, with both groups showing similar cumulative distribution patterns over the range.*

FDA Label Image

Memantine HCl Er Capsules (Ad59ebbd 2896 48a1 A53c 719c04593a9a 04)

A line graph showing the mean Clinical Interview-Based Impression of Change plus (CIBIC-plus) score over 24 weeks of treatment. The graph compares memantine hydrochloride extended-release capsules 28 mg with placebo in patients on acetylcholinesterase inhibitors (AChEI). The y-axis represents the mean CIBIC-plus score with error bars, while the x-axis shows weeks of treatment. The graph indicates clinical improvement and decline benchmarks.*

FDA Label Image

Memantine HCl Er Capsules (Ad59ebbd 2896 48a1 A53c 719c04593a9a 05)

A bar graph comparing the percentage of patients with different Clinical Interview-Based Impression of Change Plus (CIBIC Plus) ratings, including marked improvement, moderate improvement, minimal improvement, no change, minimal worsening, moderate worsening, and marked worsening. The graph compares Memantine hydrochloride extended-release capsules 28 mg combined with AChEI (black bars) versus Placebo combined with AChEI (white bars).*

FDA Label Image

Memantine Hydrochloride Extended-release Capsules, 7 mg (Ad59ebbd 2896 48a1 A53c 719c04593a9a 06)

Label for Memantine Hydrochloride extended-release capsules, 7 mg strength, oral dosage form. The label states the product is for once-daily use and comes in a bottle of 30 capsules. It includes storage instructions, manufacturer Cadila Healthcare Ltd. India, and distributor Zydus Pharmaceuticals USA Inc. The label includes a capsule image and a barcode.*

FDA Label Image

Memantine Hydrochloride Extended-release Capsules, 14 mg (Ad59ebbd 2896 48a1 A53c 719c04593a9a 07)

Memantine Hydrochloride Extended-release capsules 14 mg packaging label from Zydus Pharmaceuticals USA Inc. The label includes the dosage strength of 14 mg, indicates the capsules are extended-release, and states a 30-capsule count. It features the drug name prominently, a capsule illustration, storage instructions, and manufacturer and distributor information.*

FDA Label Image

Memantine Hydrochloride Extended-release Capsules, 21 mg (Ad59ebbd 2896 48a1 A53c 719c04593a9a 08)

Memantine Hydrochloride Extended-release Capsules 21 mg bottle label by Zydus Pharmaceuticals USA Inc. The label indicates a 30-capsule package with dosage form as extended-release capsules. It includes storage instructions, dosage note, manufacturer Cadila Healthcare Ltd., India, and distributor Zydus Pharmaceuticals USA Inc.*

FDA Label Image

Memantine Hydrochloride Extended-release Capsules, 28 mg (Ad59ebbd 2896 48a1 A53c 719c04593a9a 09)

Memantine hydrochloride extended-release capsules 28 mg label showing product name, dosage form, strength, and quantity of 30 capsules. Label includes Zydus Pharmaceuticals USA Inc. as distributor and Cadila Healthcare Ltd. as manufacturer. The label also has usage instructions for pharmacists and storage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.